Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Richardson, Paul [1 ]
Hofmeister, Craig [2 ]
Jakubowiak, Andrzej [3 ]
Zimmerman, Todd M. [5 ]
Spear, Matthew A. [4 ]
Palladino, Michael A. [4 ]
Longenecker, Angie M. [4 ]
Kelly, Susan L. [6 ]
Neuteboom, Saskia [7 ]
Cropp, Gillian F. [4 ]
Lloyd, G. Kenneth [4 ]
Hannah, Alison L. [4 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Nereus Pharmaceut Inc, San Diego, CA USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Multiple Myeloma Res Fdn, Norwalk, CT USA
[7] Nereus Pharmaceut Inc, San Diego, CA USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [1] Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)
    Hofmeister, C. C.
    Richardson, P.
    Zimmerman, T.
    Spear, M. A.
    Palladino, M. A.
    Longenecker, A. M.
    Cropp, G. F.
    Lloyd, G. K.
    Hannah, A. L.
    Anderson, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
    Richardson, Paul G.
    Spencer, Andrew
    Cannel, Paul
    Harrison, Simon J.
    Catley, Laurence
    Underhill, Craig
    Zimmerman, Todd M.
    Hofmeister, Craig C.
    Jakubowiak, Andrzej J.
    Laubach, Jacob P.
    Palladino, Michael A.
    Longenecker, Angie M.
    Lay, Ana
    Wear, Sandra
    Lloyd, G. Kenneth
    Hannah, Alison L.
    Reich, Steve
    Spear, Matthew A.
    Anderson, Kenneth C.
    BLOOD, 2011, 118 (21) : 140 - 141
  • [3] Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma.
    Richardson, Paul
    Hofmeister, Craig C.
    Zimmerman, Todd M.
    Chanan-Khan, Asher Alban
    Spear, Matthew A.
    Palladino, Michael A.
    Longenecker, Angie M.
    Cropp, Gillian
    Lloyd, G. Kenneth
    Wear, Sandra
    Hannah, Alison L.
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 955 - 956
  • [4] Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052
    Spencer, Andrew
    Millward, Michael
    Mainwaring, Paul
    Harrison, Simon
    Catley, Laurence
    Townsend, Amanda
    Sukumaran, Shawgi
    Longenecker, Angie M.
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Neuteboom, Saskia
    Padrik, Peeter
    Spear, Matthew A.
    Price, Timothy
    BLOOD, 2009, 114 (22) : 1053 - 1054
  • [5] Phase 1 clinical trial of a novel proteasome inhibitor (NPI-0052) in patients with lymphomas and solid tumors
    Kurzrock, Razelle
    Hamlin, Paul
    Younes, Anas
    Hong, David
    Gordon, Michael
    Spear, Matthew A.
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Longenecker, Angie M.
    Neuteboom, Saskia T. C.
    Cropp, Gillian F.
    Hannah, Alison
    Aghajanian, Carol
    BLOOD, 2007, 110 (11) : 198B - 198B
  • [6] A two-arm phase 1 clinical trial with NPI-0052, a novel proteasome inhibitor
    Price, Timothy
    Millward, Michael
    Mainwaring, Paul
    Harrison, Simon
    Galley, Laurence
    Townsend, Amanda
    Sukumaran, Shawgi
    Longenecker, Angie
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Neuteboom, Saskia
    Padrik, Peeter
    Spear, Matthew A.
    Spencer, Andrew
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [7] Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
    Richardson, Paul G.
    Zimmerman, Todd M.
    Hofmeister, Craig C.
    Talpaz, Moshe
    Chanan-Khan, Asher A.
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Chauhan, Dharminder
    Jakubowiak, Andrzej J.
    Reich, Steven
    Trikha, Mohit
    Anderson, Kenneth C.
    BLOOD, 2016, 127 (22) : 2693 - 2700
  • [8] PHASE 1 STUDY OF THE NOVEL PROTEASOME INHIBITOR NPI-0052 IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING LEUKEMIAS
    Padrik, P.
    Price, T. J.
    Spear, M. A.
    Townsend, A.
    Longenecker, A.
    Palladino, M. A.
    Lloyd, K. G.
    Cropp, G. F.
    Millward, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 162 - 162
  • [9] Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma
    Chauhan, Dhapminder
    Singh, Ajita V.
    Brahmandam, Mohan
    Bianchi, Giada
    Podar, Klaus
    Hideshima, Teru
    Munshi, Nikhil
    Richardson, Paul
    Palladino, Michael A.
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 1254 - 1254
  • [10] First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052
    Hamlin, P. A.
    Aghajanian, C.
    Younes, A.
    Hong, D. S.
    Palladino, M. A.
    Longenecker, A. M.
    Lloyd, G. K.
    Hannah, A. L.
    Spear, M. A.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345